Ronald D'Amico Selected Research

cabotegravir

12/2023	Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
1/2023	Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
10/2022	Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.
11/2021	Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
1/2021	Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
1/2020	Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection.
1/2020	Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ronald D'Amico Research Topics

Disease

4	Infections 01/2023 - 01/2020
3	Injection Site Reaction 12/2023 - 01/2020
3	Acquired Immunodeficiency Syndrome (AIDS) 02/2012 - 03/2005
2	Pain (Aches) 12/2023 - 01/2022
2	Malaria 02/2012 - 01/2012
1	Fatigue 12/2023
1	Viremia 01/2023
1	COVID-19 10/2022
1	HIV Infections (HIV Infection) 01/2020
1	Jaundice (Icterus) 01/2014
1	Fibrosis (Cirrhosis) 01/2014
1	Hyperbilirubinemia 01/2014
1	Hemolytic Anemia 01/2014
1	Progressive Multifocal Leukoencephalopathy 01/2007

Drug/Important Bio-Agent (IBA)

7	Rilpivirine (TMC-278)IBA 12/2023 - 01/2020
7	cabotegravirIBA 12/2023 - 01/2020
3	Ritonavir (Norvir)FDA Link 01/2014 - 01/2012
2	Nevirapine (Viramune)FDA Link 02/2012 - 01/2012
2	Lopinavir FDA Link 02/2012 - 01/2012
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2023
1	IntegrasesIBA 01/2023
1	lamivudine drug combination abacavir FDA Link 01/2020
1	dolutegravirIBA 01/2020
1	Raltegravir Potassium FDA Link 01/2014
1	dasabuvirIBA 01/2014
1	ombitasvirIBA 01/2014
1	Antiviral Agents (Antivirals)IBA 01/2014
1	BilirubinIBA 01/2014
1	Atazanavir Sulfate (Reyataz)FDA Link 01/2014
1	Ribavirin (Virazole)FDA LinkGeneric 01/2014
1	RNA (Ribonucleic Acid)IBA 01/2014
1	paritaprevirIBA 01/2014
1	Human immunodeficiency virus 1 p16 proteaseIBA 02/2012
1	octaneIBA 01/2012
1	Proteins (Proteins, Gene)FDA Link 01/2012
1	Histidine (L-Histidine)FDA Link 01/2012
1	AntigensIBA 01/2012

Therapy/Procedure

4	Injections 01/2022 - 01/2020
4	Therapeutics 01/2020 - 01/2007
3	Art Therapy 01/2014 - 03/2005
1	Contraindications 12/2023
1	Ambulatory Care (Outpatient Care) 10/2022